Boehringer Ingelheim

Latest Headlines

Latest Headlines

Boehringer touts Pradaxa antidote data as FDA decision nears

LONDON-- Boehringer Ingelheim's Pradaxa currently trails Johnson & Johnson and Bayer med Xarelto in the market for new-age anticoagulants, but the German drugmaker is hoping a nod for its antidote candidate will help turn the tide in its favor.

New Pradaxa antidote study preps Boehringer for market-share turnaround: ESC

LONDON-- Boehringer Ingelheim's Pradaxa may have been first in its class of new-age anticoagulants to hit the scene, but since then, it's lost market share to Johnson & Johnson and Bayer's contender, Xarelto. Bringing a bleeding antidote to market could give Pradaxa a boost, though, and Boehringer touted good news on that front Tuesday.

Lilly, Boehringer amp up fight against Lantus with U.K. biosim launch

It's happened: Eli Lilly & Co. and Boehringer Ingelheim have rolled out their biosimilar version of Lantus in its first major market. The U.K. launch follows some smaller rollouts in Eastern Europe--and it's the next move in a planned worldwide assault on the Sanofi diabetes stalwart.

Boehringer Ingelheim partners with telenovela for diabetes storyline

The drama is on for Boehringer Ingelheim. On TV, that is. The pharma has struck a deal with a Telemundo telenovela set in Los Angeles called "Bajo el Mismo Cielo" for a diabetes awareness campaign--and with it, BI becomes the first drugmaker with an integrated storyline on the Spanish language channel.

Boehringer upgrades study startup software tool

Boehringer Ingelheim has upgraded to the latest version of InnovoCommerce's innovoPOINT.

Boehringer trumpets Spiolto quality-of-life data as it looks for its niche in COPD

Boehringer Ingelheim's COPD treatment, Spiolto Respimat, is up against a raft of competitors--especially in the E.U., where it recently won its first approvals. Now, though, it's touting new data from a quality of life study that it hopes will give it a leg up.

Boehringer takes a neuroscience approach to obesity with latest deal

Boehringer Ingelheim is pairing up with a small California biotech to explore the role circuits in the nervous system play in obesity, scouting for drug targets that could spur weight loss.

Boehringer Ingelheim recalls more than 358,000 inhalers

Inhalers can be tricky devices to manufacture and for the second time in two weeks a drugmaker is having to recall inhalers because the devices may not deliver any drugs. Following last week's recall by AstraZeneca of asthma inhalers in Denmark, Boehringer Ingelheim is recalling in the U.S. tens of thousands of inhalers used to treat chronic obstructive pulmonary disease.

Boehringer bets up to $730M on a new lung cancer drug

Boehringer Ingelheim has agreed to hand over as much as $730 million to South Korean drugmaker Hanmi Pharmaceutical in exchange for the rights to a midstage treatment for lung cancer, betting the drug can stand out in a crowded field.

Hikma gets large U.S. plant in Boehringer Ingelheim generics deal

Last year when Hikma bought Boehringer Ingelheim's Ben Venue injectable business, it decided not to reopen its long-troubled Bedford, OH, plant. But with a $2.65 billion deal announced today for Boehringer's Roxane generics business, it gets a U.S. manufacturing plant that it says it likes the looks of.